Premium
Samidorphan, recently Schedule II, approved as psychiatric combo
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.33097
Subject(s) - olanzapine , food and drug administration , psychiatry , schizophrenia (object oriented programming) , medicine , schedule , bipolar disorder , psychology , pharmacology , lithium (medication) , management , economics
This month, the Food and Drug Administration (FDA) approved samidorphan and olanzapine, a new combination medication, for the treatment of schizophrenia and bipolar disorder. The medication sponsor is Alkermes, and the medication is called Lybalvi.